Sun Pharmaceutical Industries Ltd. engages in development, manufacturing, sell, trading, marketing and export of various pharmaceutical products. The company produces generic products targeting spectrum of chronic and acute treatments. It manufactures span generics, branded generics, difficult-to-make technology intensive products, over-the-counter, anti-retrovirals, active pharmaceutical ingredients and intermediates. The company products include dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids. Its therapeutic portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. The company operates through the following segments: U.S. Business, Indian Branded Generics Business, Emerging Markets, Rest of World, Global Consumer Healthcare Business, and Active Pharmaceutical Ingredients. Sun Pharmaceutical Industries was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.